Home › Companies › Phathom Pharmaceuticals, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Phathom Pharmaceuticals, Inc.’s Form 8-K, filed May 21, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 19, 2026: 5 items on Phathom Pharmaceuticals, Inc.’s Form 8-K, filed May 21, 2026: 3 elected · 1 approved · 1 passed (calculated).
Notable dissent: 1 director (12.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2024-2025 2025-2026
Explore Phathom Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Phathom Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 21, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Steven Basta | 42,656,800 | -- | -- | 4,490,781 | 17,487,652 | 90% | Elected | — |
| Elect Director: Theodore R. Schroeder | 42,578,532 | -- | -- | 4,569,049 | 17,487,652 | 90% | Elected | — |
| Elect Director: Mark Stenhouse | 41,249,990 | -- | -- | 5,897,591 | 17,487,652 | 87% | Elected | — |
| 2. Ratification of Independent Registered Public Accounting Firm | 64,482,757 | 49,661 | 102,815 | -- | -- | 99.9% | Approved | — |
| 3. Approval of the Compensation of the Named Executive Officers ("say-on-pay") The Company's stockholders voted and approved, on a non-binding, advisory basis, the compensation of the named executive officers | 44,449,761 | 2,532,145 | 165,675 | -- | 17,487,652 | 95% | Passed (calculated) | — |
Source: Phathom Pharmaceuticals, Inc., Form 8-K, filed with the SEC on May 21, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
185 asset managers disclosed a vote on at least one Phathom Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Steven Basta
Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Steven Basta”): 42,656,800 for, 4,490,781 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The final voting results for the matters submitted to a vote of stockholders were as follows: Proposal No. 1 - Election of Class I Directors At the Annual Meeting, the Company's stockholders elected the persons listed below as Class I directors for a three-year term expiring at the Company's 2029 A…”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Invesco | 2,973,331 | 0 | 0 | 0 | For |
| Vanguard | 1,712,484 | 0 | 6 | 0 | For |
| WASATCH FUNDS TRUST | 1,321,159 | 0 | 0 | 0 | For |
| Waddell & Reed | 0 | 0 | 0 | 727,425 | Withhold |
| Fidelity | 598,159 | 0 | 0 | 3,858 | For |
| Charles Schwab | 408,473 | 0 | 0 | 0 | For |
| BlackRock | 353,726 | 0 | 0 | 0 | For |
| Jackson National | 320,645 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 285,271 | Withhold |
| Simplify Exchange Traded Funds | 262,386 | 0 | 0 | 0 | For |
| Equitable | 246,660 | 0 | 0 | 0 | For |
| Brighthouse | 158,197 | 0 | 0 | 15,814 | Mixed |
| Ivy Variable Insurance Portfolios | 0 | 0 | 0 | 136,785 | Withhold |
| Securian Funds Trust | 0 | 0 | 0 | 116,572 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 74,857 | 0 | 0 | 0 | For |
| Goldman Sachs | 56,141 | 0 | 0 | 0 | For |
| JPMorgan | 54,504 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 0 | 0 | 0 | 53,501 | Withhold |
| AMG Funds IV | 38,268 | 0 | 0 | 0 | For |
| State Street | 36,757 | 0 | 0 | 29 | For |
| Russell Investments | 35,271 | 0 | 0 | 0 | For |
| Lincoln Financial | 33,466 | 0 | 0 | 0 | For |
| MassMutual | 33,220 | 0 | 0 | 0 | For |
| SEI | 30,576 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 27,435 | Withhold |
Fund voting reports, all 53 managers: 8,860,069 for, 1,434,235 withheld, 6 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Catalys Pacific, LLC | 1,493,854 | 0 | 0 | 0 | For |
Institutional-manager reports, all 1 managers: 1,493,854 for.
Combines 4 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Mark Stenhouse
Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Mark Stenhouse”): 41,249,990 for, 5,897,591 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The final voting results for the matters submitted to a vote of stockholders were as follows: Proposal No. 1 - Election of Class I Directors At the Annual Meeting, the Company's stockholders elected the persons listed below as Class I directors for a three-year term expiring at the Company's 2029 A…”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 8,307,410 for, 1,986,893 withheld, 7 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Invesco | 2,973,331 | 0 | 0 | 0 | For |
| Vanguard | 1,711,226 | 0 | 7 | 1,256 | For |
| WASATCH FUNDS TRUST | 1,321,159 | 0 | 0 | 0 | For |
| Waddell & Reed | 0 | 0 | 0 | 727,425 | Withhold |
| Fidelity | 598,159 | 0 | 0 | 3,858 | For |
| Charles Schwab | 0 | 0 | 0 | 408,473 | Withhold |
| BlackRock | 353,726 | 0 | 0 | 0 | For |
| Jackson National | 320,645 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 285,271 | Withhold |
| Simplify Exchange Traded Funds | 262,386 | 0 | 0 | 0 | For |
| Equitable | 216,880 | 0 | 0 | 29,780 | Mixed |
| Brighthouse | 158,197 | 0 | 0 | 15,814 | Mixed |
| Ivy Variable Insurance Portfolios | 0 | 0 | 0 | 136,785 | Withhold |
| Securian Funds Trust | 0 | 0 | 0 | 116,572 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 74,857 | 0 | 0 | 0 | For |
| Goldman Sachs | 56,141 | 0 | 0 | 0 | For |
| JPMorgan | 54,504 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 0 | 0 | 0 | 53,501 | Withhold |
| AMG Funds IV | 38,268 | 0 | 0 | 0 | For |
| State Street | 36,757 | 0 | 0 | 29 | For |
| Russell Investments | 0 | 0 | 0 | 35,271 | Withhold |
| Lincoln Financial | 33,466 | 0 | 0 | 0 | For |
| MassMutual | 33,220 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 0 | 30,576 | Withhold |
| ProShares | 0 | 0 | 0 | 27,435 | Withhold |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Description as filed by funds: To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Theodore R. Schroeder
Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Theodore R. Schroeder”): 42,578,532 for, 4,569,049 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “The final voting results for the matters submitted to a vote of stockholders were as follows: Proposal No. 1 - Election of Class I Directors At the Annual Meeting, the Company's stockholders elected the persons listed below as Class I directors for a three-year term expiring at the Company's 2029 A…”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 8,830,289 for, 1,464,015 withheld, 6 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Invesco | 2,973,331 | 0 | 0 | 0 | For |
| Vanguard | 1,712,484 | 0 | 6 | 0 | For |
| WASATCH FUNDS TRUST | 1,321,159 | 0 | 0 | 0 | For |
| Waddell & Reed | 0 | 0 | 0 | 727,425 | Withhold |
| Fidelity | 598,159 | 0 | 0 | 3,858 | For |
| Charles Schwab | 408,473 | 0 | 0 | 0 | For |
| BlackRock | 353,726 | 0 | 0 | 0 | For |
| Jackson National | 320,645 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 285,271 | Withhold |
| Simplify Exchange Traded Funds | 262,386 | 0 | 0 | 0 | For |
| Equitable | 216,880 | 0 | 0 | 29,780 | Mixed |
| Brighthouse | 158,197 | 0 | 0 | 15,814 | Mixed |
| Ivy Variable Insurance Portfolios | 0 | 0 | 0 | 136,785 | Withhold |
| Securian Funds Trust | 0 | 0 | 0 | 116,572 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 74,857 | 0 | 0 | 0 | For |
| Goldman Sachs | 56,141 | 0 | 0 | 0 | For |
| JPMorgan | 54,504 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 0 | 0 | 0 | 53,501 | Withhold |
| AMG Funds IV | 38,268 | 0 | 0 | 0 | For |
| State Street | 36,757 | 0 | 0 | 29 | For |
| Russell Investments | 35,271 | 0 | 0 | 0 | For |
| Lincoln Financial | 33,466 | 0 | 0 | 0 | For |
| MassMutual | 33,220 | 0 | 0 | 0 | For |
| SEI | 30,576 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 27,435 | Withhold |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 13 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Prior year: 73.8% for (June 3, 2025 meeting) ▲ 20.8 pts
Description as filed by funds: To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay").
Phathom Pharmaceuticals, Inc.’s own tally for this item (“3. Approval of the Compensation of the Named Executive Officers ("say-on-pay") The Company's stockholders voted and approved, on a non-binding, advisory basis, the compensation of the named executive officers”): 44,449,761 for, 2,532,145 against, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Invesco | 2,690,714 | 282,617 | 0 | 0 | Mixed |
| Vanguard | 1,711,230 | 1,259 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 1,321,159 | 0 | 0 | 0 | For |
| Waddell & Reed | 727,425 | 0 | 0 | 0 | For |
| Fidelity | 337,930 | 264,087 | 0 | 0 | Mixed |
| Charles Schwab | 408,473 | 0 | 0 | 0 | For |
| BlackRock | 353,726 | 0 | 0 | 0 | For |
| Jackson National | 320,645 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 285,271 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 262,386 | 0 | 0 | 0 | For |
| Equitable | 246,660 | 0 | 0 | 0 | For |
| Brighthouse | 174,011 | 0 | 0 | 0 | For |
| Ivy Variable Insurance Portfolios | 136,785 | 0 | 0 | 0 | For |
| Securian Funds Trust | 116,572 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 74,857 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 56,141 | 0 | 0 | Against |
| JPMorgan | 54,504 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 53,501 | 0 | 0 | 0 | For |
| AMG Funds IV | 0 | 38,268 | 0 | 0 | Against |
| State Street | 36,785 | 1 | 0 | 0 | For |
| Russell Investments | 0 | 35,271 | 0 | 0 | Against |
| Lincoln Financial | 33,466 | 0 | 0 | 0 | For |
| MassMutual | 33,220 | 0 | 0 | 0 | For |
| SEI | 0 | 30,576 | 0 | 0 | Against |
| ProShares | 27,435 | 0 | 0 | 0 | For |
Fund voting reports, all 53 managers: 9,538,792 for, 744,572 against, 10,946 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 12,466,489 | 0 | 0 | 0 | For |
| Medicxi Ventures Management (Jersey) Ltd | 7,464,572 | 0 | 0 | 0 | For |
| Invesco | 3,773,700 | 343,805 | 0 | 0 | Mixed |
| Carlyle Group Inc. | 3,496,808 | 0 | 0 | 0 | For |
| NEA Management Company, LLC | 1,960,169 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 1,807,580 | 0 | 0 | 0 | For |
| 683 Capital Management, LLC | 1,679,083 | 0 | 0 | 0 | For |
| WASATCH ADVISORS LP | 1,337,961 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 1,066,480 | 0 | 0 | 0 | For |
| BlackRock | 892,279 | 98,591 | 0 | 0 | Mixed |
| FRANKLIN ADVISERS INC | 787,684 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 694,522 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 0 | 686,873 | 0 | 0 | Against |
| EcoR1 Capital, LLC | 625,000 | 0 | 0 | 0 | For |
| Catalio Capital Management, LP | 586,041 | 0 | 0 | 0 | For |
| State Street | 563,410 | 894 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 486,678 | 0 | 0 | 0 | For |
| Charles Schwab | 408,480 | 0 | 0 | 0 | For |
| Woodline Partners LP | 362,121 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 0 | 249,390 | 0 | 0 | Against |
| Northern Trust | 211,357 | 4,296 | 0 | 0 | For |
| MARSHALL WACE, LLP | 0 | 182,890 | 0 | 0 | Against |
| AMERIPRISE FINANCIAL INC | 0 | 164,581 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 120,575 | 0 | 0 | 0 | For |
| T. Rowe Price | 104,961 | 0 | 0 | 0 | For |
Institutional-manager reports, all 147 managers: 41,788,694 for, 2,143,324 against. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 99.7% for (June 3, 2025 meeting) ▲ 0.3 pts
Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Phathom Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 64,482,757 for, 49,661 against — passed, per its Form 8-K filed May 21, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal 2026:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 10,288,364 for, 5,946 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Invesco | 2,973,331 | 0 | 0 | 0 | For |
| Vanguard | 1,712,490 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 1,321,159 | 0 | 0 | 0 | For |
| Waddell & Reed | 727,425 | 0 | 0 | 0 | For |
| Fidelity | 602,017 | 0 | 0 | 0 | For |
| Charles Schwab | 408,473 | 0 | 0 | 0 | For |
| BlackRock | 353,726 | 0 | 0 | 0 | For |
| Jackson National | 320,645 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 285,271 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 262,386 | 0 | 0 | 0 | For |
| Equitable | 246,660 | 0 | 0 | 0 | For |
| Brighthouse | 174,011 | 0 | 0 | 0 | For |
| Ivy Variable Insurance Portfolios | 136,785 | 0 | 0 | 0 | For |
| Securian Funds Trust | 116,572 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 74,857 | 0 | 0 | 0 | For |
| Goldman Sachs | 56,141 | 0 | 0 | 0 | For |
| JPMorgan | 54,504 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 53,501 | 0 | 0 | 0 | For |
| AMG Funds IV | 38,268 | 0 | 0 | 0 | For |
| State Street | 36,786 | 0 | 0 | 0 | For |
| Russell Investments | 35,271 | 0 | 0 | 0 | For |
| Lincoln Financial | 33,466 | 0 | 0 | 0 | For |
| MassMutual | 33,220 | 0 | 0 | 0 | For |
| SEI | 30,576 | 0 | 0 | 0 | For |
| ProShares | 27,435 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 79,442,367 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Invesco | 3.74% |
| 2 | Vanguard | 2.16% |
| 3 | WASATCH FUNDS TRUST | 1.66% |
| 4 | Waddell & Reed | 0.92% |
| 5 | Fidelity | 0.76% |
| 6 | Charles Schwab | 0.51% |
| 7 | BlackRock | 0.45% |
| 8 | Jackson National | 0.40% |
| 9 | FRANKLIN STRATEGIC SERIES | 0.36% |
| 10 | Simplify Exchange Traded Funds | 0.33% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 15.69% |
| 2 | Medicxi Ventures Management (Jersey) Ltd | 9.40% |
| 3 | Invesco | 5.18% |
| 4 | Carlyle Group Inc. | 4.40% |
| 5 | NEA Management Company, LLC | 2.47% |
| 6 | Ensign Peak Advisors, Inc | 2.28% |
| 7 | 683 Capital Management, LLC | 2.11% |
| 8 | WASATCH ADVISORS LP | 1.68% |
| 9 | NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 1.34% |
| 10 | BlackRock | 1.25% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Invesco | 4,322,060 | 5.44% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 4,061,996 | 5.11% | Form 13F, quarter ended March 31, 2026 |
| Millennium Management | 4,022,909 | 5.06% | Form 13F, quarter ended March 31, 2026 |
| Vanguard Group | 3,177,211 | 4.00% | Form 13F, quarter ended March 31, 2026 |
| State Street | 1,386,890 | 1.75% | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 1,328,045 | 1.67% | Form 13F, quarter ended March 31, 2026 |
| Franklin Templeton | 994,504 | 1.25% | Form 13F, quarter ended March 31, 2026 |
| Citadel Advisors | 918,158 | 1.16% | Form 13F, quarter ended March 31, 2026 |
| Goldman Sachs | 626,196 | 0.79% | Form 13F, quarter ended March 31, 2026 |
| Two Sigma | 482,136 | 0.61% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 79,442,367 shares outstanding, as reported by Phathom Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Phathom Pharmaceuticals, Inc.'s shareholder meeting held May 19, 2026, in the 2025-2026 proxy season, 185 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,047 separate fund positions. On the most widely held item on that ballot — To approve the compensation of the named executive officers on a non-binding advisory basis… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Phathom Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 21, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Phathom Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Phathom Pharmaceuticals, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Phathom Pharmaceuticals (PHAT) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/phathom-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.